Table 2.
Standardized incidence ratios, absolute excess risk, and 30-year cumulative incidence of second primary malignancies in patients with chronic lymphocytic leukemia.
| Type of SPM | No. of patients | Standardized incidence ratio (95%CI)* | Absolute excess risk per 10,000 person-years | 30-year cumulative incidence (95%CI) | ||
|---|---|---|---|---|---|---|
| All sites | 4369 | 1.63 | (1.59–1.68) | 125.06 | 69.18 | (63.50–74.71) |
| Any solid cancer | 4224 | 1.67 | (1.65–1.75) | 122.51 | 67.69 | (61.80–73.46) |
| Oral cavity or pharynx | 54 | 1.11 | (0.83–1.45 | 0.36 | 0.86 | (0.56–1.30) |
| Gastrointestinal tract | ||||||
| Esophagus | 67 | 0.99 | (0.77–1.26) | −0.03 | 1.08 | (0.66–1.75) |
| Stomach | 87 | 1.20 | (0.96–1.48) | 0.95 | 1.35 | (0.91–1.99) |
| Colon and rectum | 533 | 1.21 | (1.11–1.31) | 6.13 | 11.93 | (8.87–15.96) |
| Pancreas | 84 | 1.13 | (0.90–1.40) | 0.65 | 3.38 | (1.51–7.46) |
| Lower respiratory system | ||||||
| Larynx | 30 | 1.21 | (0.82–1.73) | 0.34 | 0.70 | (0.38–1.28) |
| Lung or bronchus | 573 | 1.36 | (1.25–1.47) | 9.98 | 13.29 | (9.51–18.41) |
| Skin | ||||||
| Melanoma | 278 | 2.74 | (2.43–3.08) | 11.72 | 4.30 | (3.38–5.45) |
| Squamous cell | 1,487 | 4.82 | (4.57–5.07) | 80.31 | 34.37 | (28.87–40.58) |
| Breast | 259 | 1.06 | (0.94–1.20) | 1.05 | 5.20 | (3.62–7.43) |
| Female genital organ | ||||||
| Endometrium | 43 | 1.04 | (0.75–1.40) | 0.11 | 0.65 | (0.45–0.96) |
| Ovary | 28 | 0.97 | (0.64–1.40) | −0.06 | 0.41 | (0.25–0.66) |
| Male genital organ | ||||||
| Prostate | 476 | 1.10 | (1.00–1.20) | 2.80 | 12.31 | (6.28–23.34) |
| Urinary tract | ||||||
| Urinary bladder or renal pelvis | 152 | 1.16 | (0.98–1.36) | 1.36 | 2.20 | (1.62–2.99) |
| Kidney | 120 | 1.73 | (1.44–2.07) | 3.36 | 3.20 | (2.23–4.59) |
| Brain | 36 | 1.35 | (0.95–1.87) | 0.62 | 1.19 | (0.61–2.34) |
| Thyroid gland | 18 | 2.12 | (1.26–3.35) | 0.63 | 0.17 | (0.11–0.28) |
| Soft-tissue sarcoma | 39 | 2.39 | (1.70–3.27) | 1.50 | 1.12 | (0.53–2.32) |
| Primary site unknown | 129 | 1.67 | (1.39–1.98) | 3.40 | 2.65 | (1.82–3.87) |
| Blood, bone marrow, or lymphatic system | ||||||
| Any hematological cancer | 224 | 1.42 | (1.24–1.62) | 4.41 | 5.07 | (3.65–7.04) |
| Non-Hodgkin lymphoma | 59 | 1.37 | (1.04–1.76) | 1.04 | 0.80 | (0.56–1.12) |
| Multiple myeloma | 40 | 1.03 | (0.74–1.40) | 0.08 | 0.72 | (0.45–1.15) |
| Acute myeloid leukemia | 56 | 2.75 | (2.08–3.58) | 2.35 | 1.90 | (0.91–3.95) |
| Myeloproliferative neoplasm | 17 | 0.66 | (0.39–1.06) | −0.57 | 0.57 | (0.22–1.47) |
| Myelodysplastic syndromes | 35 | 1.34 | (0.94–1.87) | 0.59 | 0.96 | (0.44–2.07) |
CI confidence interval, No. number.
*The listed cancers are those of which at least 10 cases were observed in the cohort. Statistically significant standardized incidence rates are presented in bold in the table.